Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVE-UC study of early versus late vedolizumab use in ulcerative colitis
NL-OMON47577Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of vedolizumab in autoimmune colitis (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Clinical and endoscopic remission at Week 26 and Clinical and endoscopic remission at Weeks 52-54. Started Dec 2015; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47577.